Journal of Ophthalmic and Vision Research · 2017 · 13 citations · 28 references
MedicineOphthalmologyPharmacotherapyClinical Vision ScienceOcular PharmacologyVisual DisordersMacular DiseaseMacular DisordersMacular Function TestingVisual AcuityVisual ImpairmentVisual Loss EvaluationCentral Vision ImpairmentFunctional Optical Coherence TomographyMacular Disease AssessmentMacular Optical Coherence TomographyMacular Thickness MeasurementSpironolactone TherapyStatic Visual AcuityVisual Acuity Gains
PURPOSE: To evaluate the effect of spironolactone on chronic central serous chorioretinopathy (CSC). METHODS: In this prospective interventional case series, patients with chronic CSC were treated with spironolactone (25 mg daily) for at least 6 weeks. If the subretinal fluid (SRF) had not completely resolved by this time, treatment was continued, and the dosage was increased to 25 mg twice daily. Primary outcome measure was the change in maximum SRF height at the final follow-up visit, as detected by optical coherence tomography. Secondary outcome measures were changes in best corrected visual acuity (BCVA) and central macular thickness (CMT). RESULTS: = 0.04). SRF resolved completely in seven eyes (43.75%). CONCLUSION: In eyes with persistent SRF due to CSC, spironolactone therapy was associated with a statistically significant decrease in maximum SRF height, as well as an improvement in BCVA.
28
Central Serous Chorioretinopathy in Younger and Older Adults
Richard F. Spaide, Laura Campeas, Anton Haas et al. · Ophthalmology · 1996 · 553 citations